Literature DB >> 22610061

Low-energy diaphyseal femoral fractures associated with bisphosphonate use and severe curved femur: a case series.

Satoshi Sasaki1, Naohisa Miyakoshi, Michio Hongo, Yuji Kasukawa, Yoichi Shimada.   

Abstract

Recent reports have raised concerns about low-energy subtrochanteric and diaphyseal femoral fractures after long-term bisphosphonate treatment, which may be associated with severely suppressed bone turnover (SSBT). However, diaphyseal femoral fractures without bisphosphonate treatment have also been reported in patients with severely curved femur, which are commonplace in the elderly. The purpose of this study was therefore to investigate associations between occurrence of such fractures, bisphosphonate use, and curvature of the femur. Nine consecutive elderly patients treated for low-energy diaphyseal femoral fractures between 2005 and 2010 were retrospectively reviewed. Three patients sustained bilateral fractures. Eight patients were administered bisphosphonates and one patient was administered raloxifene. Duration of osteoporosis treatment, type of fractures, surgical procedure, cortical thickness and curvature of opposite femur were evaluated. The cortical thickness and femoral curvature were further compared with those of 24 control subjects without fractures. The mean duration of drug administration was 3.6 years. All fractures showed similar X-ray patterns of simple transverse fracture with medial spike. Only one femur showed thickening of the femoral cortex. One case was treated with locking plate fixation, while the other cases were operated with intramedullary nails (9 antegrade nails, 2 retrograde nails). One femur treated with retrograde nail showed delayed bone union. The femoral curvature was significantly higher in the low-energy fracture group than the control group (P < 0.01); however, cortical thickness did not show a significant difference between the groups. In addition to SSBT, increased femoral curvature might be a causative factor for low-energy diaphyseal femoral fracture in the elderly.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22610061     DOI: 10.1007/s00774-012-0358-0

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN: 0914-8779            Impact factor:   2.626


  25 in total

Review 1.  Bisphosphonate adverse effects, lessons from large databases.

Authors:  Bo Abrahamsen
Journal:  Curr Opin Rheumatol       Date:  2010-07       Impact factor: 5.006

2.  Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features.

Authors:  Andrea Giusti; Neveen A T Hamdy; Olaf M Dekkers; Sharita R Ramautar; Sander Dijkstra; Socrates E Papapoulos
Journal:  Bone       Date:  2010-12-31       Impact factor: 4.398

3.  Femoral insufficiency fractures associated with prolonged bisphosphonate therapy.

Authors:  Joseph D Isaacs; Louis Shidiak; Ian A Harris; Zoltan L Szomor
Journal:  Clin Orthop Relat Res       Date:  2010-08-31       Impact factor: 4.176

4.  Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: implications for subtrochanteric femoral fracture risk.

Authors:  David B Burr; Tamim Diab; Andrew Koivunemi; Mark Koivunemi; Matthew R Allen
Journal:  J Orthop Res       Date:  2009-10       Impact factor: 3.494

5.  Low-energy femoral shaft fractures associated with alendronate use.

Authors:  Andrew S Neviaser; Joseph M Lane; Brett A Lenart; Folorunsho Edobor-Osula; Dean G Lorich
Journal:  J Orthop Trauma       Date:  2008 May-Jun       Impact factor: 2.512

6.  Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study.

Authors:  Bo Abrahamsen; Pia Eiken; Richard Eastell
Journal:  J Bone Miner Res       Date:  2009-06       Impact factor: 6.741

7.  Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study.

Authors:  B A Lenart; A S Neviaser; S Lyman; C C Chang; F Edobor-Osula; B Steele; M C H van der Meulen; D G Lorich; J M Lane
Journal:  Osteoporos Int       Date:  2008-12-09       Impact factor: 4.507

8.  Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series.

Authors:  Reina Armamento-Villareal; Nicola Napoli; Kathryn Diemer; Marcus Watkins; Roberto Civitelli; Steven Teitelbaum; Deborah Novack
Journal:  Calcif Tissue Int       Date:  2009-06-23       Impact factor: 4.333

9.  Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate.

Authors:  Ralph K H Cheung; K K Leung; K C Lee; T C Chow
Journal:  Hong Kong Med J       Date:  2007-12       Impact factor: 2.227

10.  Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack.

Authors:  Per Aspenberg; Jörg Schilcher; Anna Fahlgren
Journal:  Acta Orthop       Date:  2010-08       Impact factor: 3.717

View more
  49 in total

1.  Prophylactic Fixation Can Be Cost-effective in Preventing a Contralateral Bisphosphonate-associated Femur Fracture.

Authors:  Sam Y Jiang; David J Kaufman; Bonnie Y Chien; Michael Longoria; Ross Shachter; Julius A Bishop
Journal:  Clin Orthop Relat Res       Date:  2019-03       Impact factor: 4.176

2.  High and pointed type of femoral localized reaction frequently extends to complete and incomplete atypical femoral fracture in patients with autoimmune diseases on long-term glucocorticoids and bisphosphonates.

Authors:  H Sato; N Kondo; T Nakatsue; Y Wada; J Fujisawa; J J Kazama; T Kuroda; Y Suzuki; M Nakano; N Endo; I Narita
Journal:  Osteoporos Int       Date:  2017-04-13       Impact factor: 4.507

3.  Lateral Femoral Bowing and the Location of Atypical Femoral Fractures.

Authors:  Hyunseung Yoo; Youngho Cho; Youngbo Park; Sungsoo Ha
Journal:  Hip Pelvis       Date:  2017-06-02

Review 4.  Surgical Treatment of the Atypical Femoral Fracture: Overcoming Femoral Bowing.

Authors:  Kyung-Jae Lee; Byung-Woo Min
Journal:  Hip Pelvis       Date:  2018-12-06

5.  Factors Associated with Increased Healing Time in Complete Femoral Fractures After Long-Term Bisphosphonate Therapy.

Authors:  Hae-Seong Lim; Chong-Kwan Kim; Youn-Soo Park; Young-Wan Moon; Seung-Jae Lim; Sang-Min Kim
Journal:  J Bone Joint Surg Am       Date:  2016-12-07       Impact factor: 5.284

6.  Localized cortical thickening of the femoral diaphysis captured on an X-ray before alendronate therapy in two cases of atypical femoral fracture.

Authors:  Yoichi Iizuka; Rumi Takechi; Haku Iizuka; Takuya Omodaka; Kenji Takagishi
Journal:  Skeletal Radiol       Date:  2016-07-11       Impact factor: 2.199

7.  Atypical femoral fractures, bisphosphonates, and mechanical stress.

Authors:  Per Aspenberg; Jörg Schilcher
Journal:  Curr Osteoporos Rep       Date:  2014-06       Impact factor: 5.096

Review 8.  Atypical femoral fractures and bisphosphonate use: current evidence and clinical implications.

Authors:  Yoshitomo Saita; Muneaki Ishijima; Kazuo Kaneko
Journal:  Ther Adv Chronic Dis       Date:  2015-07       Impact factor: 5.091

Review 9.  The Role of Lower-Limb Geometry in the Pathophysiology of Atypical Femoral Fracture.

Authors:  Ifaz T Haider; Prism S Schneider; W Brent Edwards
Journal:  Curr Osteoporos Rep       Date:  2019-10       Impact factor: 5.096

10.  Location of fractures and the characteristics of patients with atypical femoral fractures: analyses of 38 Japanese cases.

Authors:  Kojiro Hyodo; Tomofumi Nishino; Hiroshi Kamada; Daisuke Nozawa; Hajime Mishima; Masashi Yamazaki
Journal:  J Bone Miner Metab       Date:  2016-03-29       Impact factor: 2.626

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.